The melanoma incidence continues to increase, and the disease remains incurable for many due to its metastatic nature and high rate of therapeutic resistance. In particular, melanomas harboring BRAF V600E and PTEN mutations often are resistant to current therapies, including BRAF inhibitors (BRAFi) and immune checkpoint inhibitors. Abl kinases (Abl/Arg) are activated in melanomas and drive progression; however, their mechanism of activation has not been established. Here we elucidate a novel link between BRAF V600E /ERK signaling and Abl kinases. We demonstrate that BRAF V600E /ERK play a critical role in binding, phosphorylating and regulating Abl localization and Abl/Arg activation by Src family kinases. Importantly, Abl/Arg activation downstream of BRAF V600E has functional and biological significance, driving proliferation, invasion, as well as switch in epithelial-mesenchymal-transition transcription factor expression, which is known to be critical for melanoma cells to shift between differentiated and invasive states. Finally, we describe findings of high translational significance by demonstrating that Abl/Arg cooperate with PI3K/Akt/PTEN, a parallel pathway that is associated with intrinsic resistance to BRAFi and immunotherapy, as Abl/Arg and Akt inhibitors cooperate to prevent viability, cell cycle progression and in vivo growth of melanomas harboring mutant BRAF/PTEN. Thus, these data not only provide mechanistic insight into Abl/Arg regulation during melanoma development, but also pave the way for the development of new strategies for treating patients with melanomas harboring mutant BRAF/PTEN, which often are refractory to current therapies.
INTRODUCTION
Unlike most cancers, melanoma diagnoses are increasing, particularly in young women ( o40), and the disease remains incurable for many with metastatic disease (18%, 5-year survival rate; https://seer.cancer.gov/data/citation.html). Immunotherapies hold promise for increasing the cure rate for a proportion of advanced cases; however, for patients with high metastatic burden, immunotherapy often is not a first-line option, due to the time needed to achieve a response. 1 Moreover, only a subset of patients respond. 2, 3 Constitutive activation of the BRAF serinethreonine kinase (BRAF V600E ) is the most common genetic change in melanoma. [3] [4] [5] It is frequently mutated in melanomas derived from intermittent sun exposure (80-90%) and early onset (age ⩽ 39; 86%). [4] [5] [6] [7] BRAF also is mutated in benign nevi (50-60%) where it promotes senescence due to high-level, sustained ERK activation. 8, 9 Activation of the PTEN/PI3K/Akt pathway, which modestly down-modulates BRAF/ERK signaling, promotes escape from oncogene-induced senescence and subsequent progression. 8, 9 BRAFi reduce metastatic burden for some patients with BRAF V600E -expressing melanomas; however, the majority of responding patients rapidly develop resistance, and combined BRAF/MEK inhibitor therapy (BRAFi/MEKi) only delays resistance. 1, 10 Moreover, BRAFi/MEKi often are less effective for melanomas harboring activation of the PI3K/Akt pathway (for example, PTEN loss), which frequently occurs concurrently with BRAF mutations, inducing cytostatic rather than cytotoxic effects, and PTEN mutations also are associated with intrinsic resistance to immunotherapy. 3, [11] [12] [13] [14] [15] Thus, it is imperative to identify new drug combinations for treating these patients.
Melanomas originate from neural crest-derived melanocytes, and thus, do not undergo classical epithelial-mesenchymal-transition (EMT). 16 Instead, melanoma cells are highly plastic, and switch between differentiated and invasive states, which contributes to the high rate of metastasis and drug resistance. 16 This phenotypic shift has been linked to BRAF V600E -induced switch in expression of EMT transcription factors (EMT-TF) from ZEB2 and SNAIL2, which display tumor suppressive properties, to ZEB1 and TWIST1, which cooperate with BRAF V600E to induce invasion and tumor growth. 17 The switch is driven, in part, by ERK-dependent induction and phosphorylation of FRA-1, a member of the AP-1 transcription factor family, which binds ZEB1, ZEB2 and TWIST1 promoters and regulates their transcription. 17 TWIST1 and ZEB1 also are regulated by other pathways as SQSTM1/p62 stabilizes TWIST1 protein; FOXD3, represses TWIST1 transcription; and ZEB2 induces microphthalmiaassociated transcription factor, which represses ZEB1. [18] [19] [20] The Abelson non-receptor tyrosine kinases, Abl (ABL1) and Arg (ABL2), are most known for their involvement in human leukemia; however, accumulating evidence over the past decade indicates the kinases also have oncogenic roles in solid tumors. [21] [22] [23] We and others reported that Abl/Arg are activated in melanoma, and drive invasion, proliferation, survival and late stages of metastasis via unique pathways. 22, [24] [25] [26] [27] [28] However, to date, little is known regarding the mechanism of Abl/Arg activation. In the current study, we show that BRAF V600E plays a critical role in activating Abl/Arg, which is required for BRAF V600E induction of the EMT-TF switch, proliferation and invasion, and Abl/Arg also feedback and potentiate BRAF/ERK signaling. Moreover, Abl/Arg synergize with Akt, a parallel, cooperating pathway, to drive survival, cell cycle progression and in vivo growth of mutant BRAF/PTEN melanomas.
Thus, these data not only uncover a novel link between Abl/Arg and BRAF V600E signaling, but also identify a promising therapeutic strategy for treating patients with melanomas harboring BRAF/PTEN mutations. 
RESULTS
Abl/Arg are overexpressed and activated in melanoma cell lines, and promote invasion and proliferation Previously, we showed that Abl and Arg were highly expressed in six melanoma lines and activated in a subset (60%). 24 Here we expanded these studies to 25 human melanoma cell lines. Abl/Arg were overexpressed in nearly all lines (compared to melanocytes), and a subset (40-60%) also had high basal Abl/Arg activities as determined directly by in vitro kinase assay, and indirectly via phosphorylation of endogenous Abl/Arg substrates, Crk and CrkL, on Abl/Arg phosphorylation sites (Supplementary Figure S1A and Supplementary Table S1 ; denoted pCrkL). pCrkL was highly correlative with Abl+Arg but not Src activity, confirming that it is a reliable readout of Abl+Arg activity (Supplementary Figure S1B ). 26, 29, 30 Previously, we showed that inhibition of Abl and Arg with first (imatinib) or second (nilotinib) generation inhibitors, or silencing Abl/Arg with two independent siRNAs, dramatically reduced proliferation and invasion (matrigel, 3D) of WM3248 and 435s melanoma lines, which have high Abl/Arg activities (Supplementary Figure S1A ). 24, 25 Here we identified additional lines with high activity (UACC-903 and LOX-IVMI; Supplementary Figure S1A ), and demonstrate that Abl/Arg inhibition with nilotinib or GNF-2/GNF-5 (highly specific but less potent allosteric inhibitors), 23, 30 or silencing Abl/Arg with siRNAs reduced proliferation and invasion in these lines (Supplementary Figures S1C and D). 24, 25 Moreover, stable expression of an shRNA targeting both Abl and Arg also reduced invasion (Supplementary Figure S1E ). Thus, Abl and Arg are activated in a subset of melanoma lines and drive proliferation and invasion. Cell lines with high Abl/Arg activities (435s, WM3248, UACC-903, LOX-IVMI) were used for subsequent studies.
BRAF V600E activates Abl/Arg Previously, we showed that pCrkL, a highly accepted readout of Abl+Arg activities (Supplementary Figure S1A ), 26, 29, 31 was elevated in a subset of primary melanomas (40-60%) using two independent melanoma tissue microarrays. 24, 25 Abl/Arg activation was high in patients who were diagnosed with melanomas at an early age (⩽ 39; 86%), and in melanomas derived from intermittent sun exposure (61%). 25 Interestingly, BRAF mutations also occur most frequently in early-onset (74%) melanomas, and in melanomas from the intermittent sun exposure subtype (80-90%). [4] [5] [6] [7] Thus, we hypothesized that the activities of Abl/Arg and BRAF V600E might be linked. To test whether BRAF V600E contributes to Abl/Arg activation, BRAF activity was blocked with two independent inhibitors (SB590885, PLX-4720-vemurafenib analog), and Abl/Arg activity assessed indirectly (pCrkL; Figure 1a ), and directly (in vitro kinase assay; Figure 1b ), in cell lines harboring BRAF V600E and highly active Abl/Arg (WM3248, 435s). Both drugs have little/no activity toward Abl (Abl1). 32, 33 Abl/Arg kinase activities and pCrkL were reduced following BRAF V600E inhibition (Figures 1a and b ), even as early as 1-4 h after drug treatment (Figure 1b , right). These results were not due to off-target effects or direct inhibition of Abl/Arg by the drugs, as silencing BRAF V600E also reduced pCrkL and Abl/Arg activities (confirmed in a third cell line and with a second siRNA; Figure 1c ). Thus, BRAF V600E signaling activates Abl/ Arg in melanoma cells.
To examine whether BRAF V600E expression is sufficient to activate Abl/Arg, we performed gain-of-function experiments using murine melan-a melanocytes, since unlike human melanocytes, introduction of BRAF V600E is sufficient to induce their transformation and does not induce senescence. 17 Consistent with our studies in human melanoma cells, introduction of BRAF V600E into melan-a cells induced pCrkL and activated Arg; however, Abl activity was reduced, likely due to decreased Abl protein (Figures 1d and e ). Importantly, Abl loss was due to its translocation to a triton-Xinsoluble compartment as increased Abl levels were observed in radio-immunoprecipitation assay buffer (RIPA)-solubilized pellets from cells expressing BRAF V600E (Figure 1e , bottom). These data indicate that BRAF V600E might alter Abl localization. Unlike Arg, which is only present in the cytoplasm/plasma membrane, Abl resides in the nucleus, cytoplasm and plasma membrane, and can shuttle between nuclear and cytoplasmic compartments. 34 Activation of nuclear Abl induces apoptosis, which contrasts with its transforming role in the cytoplasm. 22 To examine whether BRAF V600E alters Abl localization, infected melan-a cells were subjected to subcellular fractionation and immunofluorescence. Importantly, introduction of BRAF V600E increased expression of Abl in the cytoplasm and in long membranous extensions, and reduced its levels in the nucleus (Figure 1f and Supplementary Figure S2 ). These data show for the first time that BRAF V600E signaling plays a crucial role in activating Abl and Arg and impacts Abl localization, which is critical for its function. Consistent with Abl/Arg and BRAF V600E acting within the same pathway, nilotinib and the BRAFi, PLX-4720, did not cooperate to inhibit melanoma proliferation (Supplementary Figure S3 ). BRAF V600E binds Abl/Arg SH3 domains, and induces Abl/Arg phosphorylation To unravel the mechanism by which BRAF V600E promotes Abl/Arg activation, we first tested whether the proteins are in the same complex. Indeed, Abl and Arg bound to BRAF V600E in a heterologous system (Figure 2a ), as well as in melanoma cells and ERK was in the same complex ( Figure 2b ). Importantly, Glutathione-S-transferase (GST) pull-down assays demonstrated that BRAF V600E but not ERK directly bound Abl and Arg SH3 domains ( Figure 2c ). Abl/Arg are inhibited by SH3 domaininterlinker proline intramolecular interactions, and binding of proteins to the SH3 domain relieves autoinhibition. 21, 22 Thus, BRAF V600E binding could induce Abl/Arg autoactivation. However, catalytically inactive BRAF (D594A) retained the ability to bind Abl, indicating that BRAF binding is not sufficient to activate Abl (Figure 2d ). Rather, BRAF V600E , a serine-threonine kinase, induced Abl threonine phosphorylation (Figure 2e ), and tyrosine phosphorylation of kinase-inactive Abl or Arg, which lack the ability to autophosphorylate (Figure 2f ). Thus, BRAF V600E likely promotes Abl/Arg phosphorylation by tyrosine kinases that regulate their activities. 21, 22 Indeed, Src family tyrosine kinases (SFKs) activate Abl and Arg in melanoma cells (Figure 2g ), as we demonstrated in other cell types, 35, 36 and SFK inhibition prevented BRAF V600E from Abl/Arg are required for BRAF-mediated switch in EMT-TF expression, proliferation and invasion, and potentiate BRAF V600E signaling To understand the functional and biological significance of Abl/Arg activation by BRAF/ERK, we examined whether Abl/Arg act downstream of BRAF V600E to promote BRAF-driven processes. 17 Expression of BRAF V600E induces ERK-dependent expression and phosphorylation of FRA-1, which causes a switch in EMT-TF expression from ZEB2/SNAIL2 to ZEB1/TWIST1. 17 Consistent with these data, ERK1/2 and FRA-1 were constitutively phosphorylated in melanoma cells that naturally express BRAF V600E (WM3248, UACC-903, 435s; Figure 4a ). Transfection of siRNAs targeting Abl or Arg, expression of an shRNA that silences Abl and Arg or treatment with the Abl/Arg inhibitor, nilotinib, reduced pERK1/2, pFRA-1/FRA-1, ZEB1 and TWIST1 expression, and induced ZEB2 (Figures 4a and b and Supplementary Figures S4A and B) , indicating that Abl and Arg activation is required for the EMT-TF switch. Consistent with these data, there was a strong trend (Pearson correlation coefficient = 0.3, P = 0.06; n = 40) toward a correlation between Arg (ABL2) and TWIST1 mRNA expression in human melanoma metastases (Oncomine Riker data set), 37 which became highly significant when the n was increased by including all skin cancer samples (Spearman correlation coefficient = 0.29, P = 0.01; n = 82). To test whether Abl and/or Arg mediate the effects of BRAF V600E on the switch, we examined whether expression of constitutively active forms of Abl or Arg (PP) 38 (using a cumate-inducible system), could rescue reversion of the EMT-TF switch induced by inhibiting BRAF in melanoma cells harboring BRAF V600E . As expected, treatment of vector-transfected cells with the BRAF inhibitor, PLX-4720 (24 h), reversed the EMT-TF switch, inhibiting pERK1/2 and pFRA-1/FRA-1, ZEB1 and TWIST1 expression, and inducing ZEB2 (Figures 4c and d) . Notably, expression of Abl-PP rescued the effects of PLX-4720 on TWIST1 and ZEB1, and completely rescued PLX-4720-mediated inhibition of TWIST1 at shorttreatment times (2 h; Figures 4c and d, right ; Supplementary  Figure S4C ). Effects were observed in the absence of cumate due to promoter leakiness (Figure 4c ), and were enhanced in the presence of cumate (Figure 4d ). In contrast, neither Abl-PP nor Arg-PP rescued PLX-4720 effects on pERK or pFRA-1/FRA-1. Thus, Abl is required for BRAF-driven induction of the EMT-TF switch, and induces TWIST1/ZEB1 in an ERK-and FRA-1-independent manner. Interestingly, Abl-PP and/or Arg-PP expression also increased pFRA-1/FRA-1, pERK1/2, TWIST1 and ZEB1 expression in the absence of PLX-4720 (Figures 4c and d, left) , indicating that Abl/ Arg also potentiate BRAF V600E induction of the EMT-TF switch, in addition to Abl acting downstream of BRAF V600E . In summary, Abl and Arg activation is required to induce the EMT-TF switch; Abl acts downstream of BRAF V600E to regulate TWIST1/ZEB1 expression in an ERK-and FRA-1-independent manner; and Abl/Arg activation potentiates BRAF V600E -mediated induction of the EMT-TF switch. These data are the first to link Abl/Arg activation with the EMT-TF switch, which is a critical step in melanoma progression.
Switch in EMT-TF expression is linked to increased melanoma proliferation and invasion. 17, 18, 39 Thus, we tested whether Abl/Arg are required for BRAF-driven proliferation and invasion. Significantly, Abl-PP+Arg-PP expression completely rescued inhibition of proliferation induced by silencing BRAF V600E (Figure 4e ; compare last two bars), indicating that Abl/Arg activation downstream of BRAF is required for BRAF-driven proliferation. In contrast, Abl-PP +Arg-PP expression only partially rescued BRAF siRNA-mediated inhibition of matrigel invasion (Figure 4f , compare last two bars), which likely is due, at least in part, to BRAF siRNA-mediated inhibition of exogenous Abl/Arg activity (pCrkL) in serum-free conditions (Figure 4f Abl/Arg cooperate with Akt to promote melanoma growth and survival Since cancers rapidly develop resistance to targeted agents, the future of targeted therapy lies in targeting cooperating, compensatory pathways. Melanomas with PTEN mutations (activation of Akt), which frequently occurs concurrently with BRAF mutations, often are intrinsically resistant to therapy, indicating a need for new therapies for these patients. 3, [11] [12] [13] [14] Since Abl/Arg are activated in mutant BRAF/PTEN melanomas (for example, WM3248, UACC--903; Supplementary Figure S1 and Supplementary Table S1 ), and have little impact on Akt signaling in non-stress conditions, 40 we hypothesized that Abl/Arg and Akt lie in parallel, cooperating pathways. Indeed, inhibitors targeting Abl/Arg (nilotinib; FDAapproved) and Akt (MK-2206; allosteric inhibitor) potently synergized to reduce viability of mutant PTEN melanoma cells expressing highly active Abl and Arg (Figures 5a and b) . Nilotinib also cooperated with MK-2206 to block colony formation following drug removal/washout, indicating that the effects are permanent (Figures 5c and d) . Moreover, nilotinib's effects were Abl/Arg-dependent and not mediated by off-target or other ontarget effects, as GNF-5 treatment (Figure 5d ) or expression of an shRNA targeting both Abl and Arg (Figure 5e ), also efficiently prevented colony formation of cells treated with MK-2206, even when colonies were allowed to form for 8 days prior to treatment (Figure 5d ). Importantly, the mechanism of drug synergy involved G1-4S cell cycle arrest (Figure 5f and Supplementary Figure S5 ), and induction of markers for apoptosis (PARP cleavage) and G1 arrest/senescence/dormancy (↑p27, ↓pRB; Figure 5g ). Figures 6a and b) . Moreover, nilotinib, MK-2206 and the combination did not significantly alter animal body weight (Figure 6c ) or induce other signs of toxicity (for example, anemia-pale paws and so on). Similar to in vitro results, the drug combination inhibited RB phosphorylation (an indicator of G1 arrest) in the small residual tumors (30-100 mm 3 ) from combination-treated animals (Figure 6d ). Importantly, nilotinib's effects were Abl/Arg-dependent (not due to off-target or other ontarget effects) as silencing Abl and Arg with an shRNA targeting both proteins, also significantly sensitized xenografts to MK-2206 treatment (Figure 6e ). Taken together, these data indicate that targeting Abl/Arg together with Akt may be an effective treatment strategy for mutant BRAF/PTEN melanomas.
DISCUSSION
This study establishes a novel functional link between BRAF V600E and Abl family kinases. We identify a new mechanism of Abl/Arg activation, and demonstrate that their activation has important functional consequences downstream of BRAF V600E and also feedback and potentiate BRAF/ERK signaling (Figure 7) . Moreover, we report data of major translational significance by showing that Abl/Arg and Akt inhibitors potently cooperate to prevent the growth of mutant BRAF/PTEN xenografts. Abl/Arg proto-oncogenes are tightly regulated, and are kept in an inactive state via intramolecular interactions. 21, 22 We show that BRAF V600E directly binds Abl/Arg SH3 domains, which bind conserved PxxP-binding motifs. 41 BRAF contains five PxxP motifs, and one is highly similar to those found in other Abl-SH3-binding proteins. 41 Interestingly, BRAF binding is insufficient to induce Abl/ Arg activation, but rather serves to recruit the kinases to the signaling complex, which, interestingly, is dependent on SFK activity.
We provide the first evidence that Abl/Arg drive the EMT-TF switch, which contributes to melanoma metastasis and drug resistance. 16 Abl/Arg activity is required for FRA-1 expression/ phosphorylation, induction of TWIST1 and ZEB1 and repression of ZEB2. Moreover, Abl drives TWIST1/ZEB1 expression downstream of BRAF V600E independent of FRA-1/ERK, which indicates that regulation of the switch may not follow a simple linear pathway (FRA-1-4ZEB1/TWIST1), and likely involves multiple levels of regulation. Consistent with these data, TWIST1 and ZEB1 also are regulated via other mechanisms, seemingly independent of ERK/FRA-1 signaling. [18] [19] [20] In addition to mediating BRAF induction of the EMT-TF switch, Abl/Arg also are required for BRAF-driven proliferation, which might occur via effects on TWIST1/ZEB1, since TWIST1/ZEB1 not only promote invasion, but also drive melanoma proliferation and cancer stem cell features (Figure 7) . 17, 18, 39, 42 Interestingly, in addition to acting downstream of BRAF V600E , Abl/ Arg also potentiate proliferation, invasion and the EMT-TF switch in the presence of BRAF V600E . Importantly, Abl/Arg induce BRAF V600E expression, as Abl-PP and Arg-PP increase BRAF V600E protein, whereas silencing Abl/Arg reduces BRAF V600E expression ( Supplementary Figure S6) . Thus, Abl/Arg likely potentiate BRAF V600E signaling by increasing BRAF V600E expression. Alternatively, it is also possible that Abl/Arg affect the activity of upstream proteins (for example, Ras or RTKs). 43, 44 BRAFi reduce proliferation and metastatic burden, but often are inefficient at preventing viability, and their lack of permanent effects results in resistance. 10 MEKi extend survival for patients with BRAFi resistance, but have on-target toxicity, and recurrent disease is aggressive and refractory to treatment (including immunotherapy) due to activation of STAT3-dependent invasion. [45] [46] [47] Moreover, patients whose melanomas harbor PTEN mutations often are less responsive to BRAFi/MEKi and immune checkpoint inhibitors. 3, [11] [12] [13] [14] In contrast to BRAFi/MEKi, Abl/Arg inhibitors block STAT3 activation, invasion and metastasis. 24, 25 Furthermore, combined inhibition of Abl/Arg and Akt pathways, in melanomas harboring mutant BRAF/PTEN, permanently inhibits colony formation (even when drugs are introduced after colonies develop), induces apoptosis and cell cycle arrest and dramatically prevents melanoma growth in vivo. These data are of high translational significance as they indicate that dual inhibition of Abl/Arg and Akt may represent a novel synthetic lethal strategy, and thus, could pave the way for the development of a novel drug combination for patients harboring mutant BRAF/PTEN melanomas (intermittent sun exposure subtype), which often are resistant to therapy. Importantly, Abl and Arg are successful drug targets in other cancer types, 21 and Abl/Arg inhibitors that also block c-Kit activity (imatinib and nilotinib) have been successfully used to treat melanomas harboring c-Kit mutations (acral, mucosal and chronic sun exposure subtypes). 48, 49 The availability of a plethora of drugs targeting Abl and Arg, which are relatively non-toxic and several of which are FDA-approved, is likely to facilitate rapid translation of these findings to the clinic.
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